Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.78 - $5.92 $48,950 - $162,800
27,500 New
27,500 $145,000
Q2 2023

Aug 23, 2023

BUY
$1.0 - $3.86 $6,900 - $26,634
6,900 Added 55.2%
19,400 $44,000
Q1 2023

May 15, 2023

BUY
$0.65 - $0.92 $8,125 - $11,500
12,500 New
12,500 $10,000
Q2 2022

Aug 15, 2022

SELL
$0.87 - $2.03 $11,919 - $27,810
-13,700 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.46 - $2.48 $20,002 - $33,976
13,700 New
13,700 $22,000
Q4 2021

Feb 14, 2022

SELL
$2.34 - $5.31 $74,178 - $168,327
-31,700 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$1.89 - $8.53 $59,913 - $270,401
31,700 New
31,700 $200,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.